Avalo Therapeutics(us:AVTX)
8.91
-1.87%
Updated on 2024-12-22
Open:9.10
Close:8.91
High:9.81
Low:8.67
Pre Close:9.08
Volume:949861.00
Amount:8.54M
Turnover:9.06%
Shares:10.49M
MarketCap:93.45M
About Avalo Therapeutics Company
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Company Name: Avalo Therapeutics
Company Address: 540 Gaither Road,Suite 400
Employees: 19
Fiscar Year: 12-31
IPO Date: 2015-11-13
Website: http://www.cerecor.com
CIK: 1534120
View all SEC Filings
About
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Address:540 Gaither Road,Suite 400
Website:http://www.cerecor.com
Market Movers